Executive Committee

About the Executive Committee

Roche’s executive team is the company's senior management and decision making body. The Executive Committee of Roche, chosen by the Board of Directors, is responsible for the day-to-day business operations.

Corporate Executive Committee
Chief Executive Officer Roche Group
CEO Roche Diagnostics
Designated CEO Roche Group as of 15 March 2023 and ad interim CEO Roche Pharmaceuticals
Chief Financial & Information Officer
Chief People Officer
Enlarged Corporate Executive Committee
Head of Genentech Research & Early Development (gRED)
Head of Roche Pharma Research & Early Development (pRED)
Global Head of Pharma Partnering
Head of Group Communications
General Counsel
Secretary to the Corporate Executive Committee
Name (year of birth)
Former Members of the Corporate Executive Committee (CVs as per end of term)

CVs as per end of 2013-2022

Zur deutschen Version

According to the guidelines for security holdings, since 2012 members of the Corporate Executive Committee are required to hold Roche securities as outlined in the Annual Report 2021, page 187, 5.14.
Members of the Corporate Executive Committee are now required to hold Roche securities equivalent in value to 200% (previously 100%) of their respective annual base salary. This requirement must be fulfilled within five years from 15 March 2022 or, in the case of new members, within five years from the start of employment.
The requirement of Roche security holdings for the CEO Roche Group remains unchanged at 500% of his annual base salary.

Möchten Sie den Inhalt auf Deutsch lesen?

Zur deutschen Version

Guidelines for security holdings

Discover more